FRESENIUS SE+CO.KGAA O.N. overview

EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Investment Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to no less than 25% plus one share 03-March-2025 / 18:03 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. THIS ANNOUNCEMENT,...

EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Change in Forecast Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024 07-May-2024 / 21:19 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024 Fresenius raises its full-year outlook...

EQS-News: Fresenius SE & Co. KGaA / Announcement of the Convening of the General Meeting Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2024 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution 02.04.2024 / 15:06 CET/CEST Announcement according to article 121 AktG (German Stock Companies Act), transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for...

EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Dividend Fresenius SE & Co. KGaA: Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023 05-Dec-2023 / 21:29 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this...

SAN DIEGO, CA / ACCESSWIRE / August 1, 2023 / Prometheus Laboratories Inc. ("Prometheus") today announced a collaboration with Fresenius Kabi to support the validation of and access to Anser ® therapeutic drug monitoring (TDM) services for eligible patients receiving the Fresenius Kabi biosimilar, IDACIO ® (adalimumab-aacf). Anser testing is utilized by clinicians treating immune-mediated diseases such as Inflammatory Bowel Disease (IBD) and Rheumatoid Arthritis (RA) to gain objective...

EQS-News: Fresenius SE & Co. KGaA / Announcement of the Convening of the General Meeting Fresenius SE & Co. KGaA: Announcement of the Convening of the General Meeting in Frankfurt am Main on 17.05.2023 according to article 121 AktG (German Stock Companies Act) with the objective of Europe-wide distribution 30.03.2023 / 15:13 CET/CEST Announcement according to article 121 AktG (German Stock Companies Act), transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for...